These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 25935702)

  • 1. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A precision, personalized approach to the management of bladder cancer.
    Apolo AB; Burger M
    Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
    [No Abstract]   [Full Text] [Related]  

  • 3. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Kacew A; Sweis RF
    Front Immunol; 2020; 11():575258. PubMed ID: 33224141
    [No Abstract]   [Full Text] [Related]  

  • 5. PD-L1 Antibody Comparison in Urothelial Carcinoma.
    Rijnders M; van der Veldt AAM; Zuiverloon TCM; Grünberg K; Thunnissen E; de Wit R; van Leenders GJLH
    Eur Urol; 2019 Mar; 75(3):538-540. PubMed ID: 30497882
    [No Abstract]   [Full Text] [Related]  

  • 6. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    Pal SK; Agarwal N; Boorjian SA; Hahn NM; Siefker-Radtke AO; Clark PE; Plimack ER
    J Clin Oncol; 2016 Sep; 34(27):3346-8. PubMed ID: 27458279
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathology of urothelial carcinoma.
    Lopez-Beltran A; Cimadamore A; Montironi R; Cheng L
    Hum Pathol; 2021 Jul; 113():67-83. PubMed ID: 33887300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Future of Precision Oncology for the Treatment of Solid Tumors.
    Klute KA
    Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
    [No Abstract]   [Full Text] [Related]  

  • 11. Bladder cancer: molecular determinants of personalized therapy.
    Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
    Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for advanced urothelial cancer of the bladder: where do we stand?
    Zhu Z; Shen Z; Xu C
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1081-7. PubMed ID: 22583418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathology in therapeutics: where are we now, and where are we going?
    Harrison DJ; Faratian D
    Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
    [No Abstract]   [Full Text] [Related]  

  • 14. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 16. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 17. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy.
    Cimadamore A; Scarpelli M; Santoni M; Cheng L; Lopez-Beltran A; Montironi R
    Expert Rev Mol Diagn; 2018 Dec; 18(12):1021-1028. PubMed ID: 30452305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.